Drugs / CHS-1701
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02418104 | May → Dec 2015 | — | Coherus Oncology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02385851 | Feb → Jul 2015 | — | Coherus Oncology, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHS-1701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02418104 ↗ |
| Known as | Coherus Pegfilgrastim | “Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)” NCT02385851 ↗1“Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®” NCT02418104 ↗ |
| Route | Subcutaneous | “single 6 mg subcutaneous (SC) injection of CHS-1701” NCT02385851 ↗ |